❖ BIOTECH 6 MONTHS HORIZON RESOLVES 15 MAY 2027 · in 6mo

The FDA approves uniQure's Huntington's disease gene therapy by May 1, 2027.

The FDA accepted uniQure's accelerated approval application with a PDUFA target decision date set for May 1, 2027.

Across 6 frontier models answering independently, the panel is barely on the yes side: the median is 63%.

They broadly agree, 12 points between Gemini at 74% and Claude at 62%.

Nothing is settled until 15 May 2027, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • GeminiGoogle

    Approval hinges on the FDA advisory committee affirming AMT-130's surrogate biomarker data in Huntington's disease.

    • FDA priority review filings accepted under accelerated pathways historically achieve on-time approval roughly 70-80% of the time.
    • Huntington's has zero disease-modifying therapies, giving uniQure intense regulatory flexibility if surgical delivery safety holds.
    • A standard three-month major amendment PDUFA extension would push the final decision to August 2027, past the May 15 deadline.
    google/gemini-3.8-flash · asked 16 Nov 2026
    74%
  • QwenAlibaba

    Turns on whether FDA accepts the Phase 1/2 biomarker data and CMC package without requesting additional evidence.

    • PDUFA approval rate for accepted filings is ~85-90%, but gene therapies face higher CRL rates due to CMC issues—Hemgenix and Roctavian both had manufacturing-related…
    • AMT-130's evidence rests on NfL reduction from a small Phase 1/2 cohort; FDA's post-2022 stance on accelerated approvals has tightened, raising the bar for surrogate…
    • A CRL requesting additional manufacturing data or a confirmatory trial design would be the most likely failure mode; an AdCom referral would signal trouble but not…
    qwen/qwen3.8-max-0902 · asked 16 Nov 2026
    64%
  • GPTOpenAI

    The decision hinges on whether FDA accepts surrogate neurofilament evidence as reasonably likely to predict benefit.

    • FDA must act by the May 1, 2027 PDUFA date; acceptance indicates the filing cleared its initial completeness review.
    • Accelerated approvals on novel neurodegenerative endpoints are less reliable than oncology precedents, but a filed BLA is materially advanced.
    • A safety signal, weak external-control analysis, or an advisory-committee rejection would sharply lower the odds.
    openai/gpt-5.6-terra · asked 16 Nov 2026
    63%
  • ClaudeAnthropic

    Hinges on FDA accepting uniQure's biomarker-based accelerated approval package without requiring further data.

    • FDA accepted the BLA for priority review with a firm PDUFA date of May 1, 2027, indicating no major filing deficiencies so far.
    • Accelerated approval pathways for rare, fatal genetic diseases with no treatment options often succeed, especially after FDA's constructive prior interactions with…
    • Risk comes from AdCom scrutiny of small/open-label trial data or a late-cycle request for more information, which could push approval past the date or cause a CRL.
    anthropic/claude-sonnet-5 · asked 16 Nov 2026
    62%
  • GrokxAI

    FDA must issue an approval letter on or before the 1 May 2027 PDUFA date.

    • BLA already accepted under accelerated review, so the statutory clock is running with no further filing hurdles.
    • Priority BLAs historically clear first-cycle ~70 % of the time, but AMT-130’s small, uncontrolled natural-history dataset sits below that base rate.
    • An AdCom vote against or a CMC/comparability hold would force a delay or CRL past 1 May.
    x-ai/grok-4.6 · asked 16 Nov 2026
    62%
  • DeepSeekDeepSeek

    Turns on whether FDA accepts CSL Behring's BLA manufacturing data for AMT-130, since the clinical package is already filed.

    • uniQure filed the BLA and FDA set a PDUFA date of May 1, 2027, so the clock is running and the decision is scheduled inside the window.
    • Accelerated approval for a rare neurodegenerative disease with a biomarker endpoint has a decent precedent, but uniQure's prior FDA interactions and the CSL…
    • The main swing factor is a mid-cycle FDA information request or CRL on CMC; a clean Type A meeting outcome by early 2027 would push me toward 75.
    deepseek/deepseek-v4.1-flash · asked 16 Nov 2026
    62%

6 of 6 models answered · 12 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 16 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.